Greenridge analyst William Gregozeski lowered the firm's price target on Jupiter Neurosciences to $25 from $30 and keeps a Buy rating on the shares after the company announced last week that it entered into a $20M Standby Equity Purchase Agreement with Yorkville Advisors. The firm added in the cash and dilutive impact from the initial $6M advance and is assuming the notes are repaid with stock at $1.50 per share, the analyst noted.
